Lupin launches asthma drug in the US

HOME » BUSINESS » HEALTHCARE » Lupin launches asthma drug in the US

Pharmaceutical major Lupin said it launched the asthma drug Budesonide Inhalation Suspension ampules in the US market.  

Budesonide Inhalation Suspension ampules are a generic equivalent of Pulmicort Respules Inhalation Suspension drugs of UK-based pharma firm AstraZeneca.

Budesonide Inhalation Suspension ampules had annual sales of approximately USD 385.4 million in the US.

Budesonide is used to control and prevent symptoms such as wheezing and shortness of breath caused by asthma.

The medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways.

It is also used as a prophylactic therapy in children from 12 months to 8 years of age.

Lupin had received approval from the United States Food and Drug Administration for sales of Budesonide Inhalation Suspension ampules in November 2018.

Mumbai-based Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.

It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.

(Now you can get topic-based alerts via WhatsApp)


Sign up to get the latest Pharma-related news delivered via email:

Don't forget to click on the activation link we send to your email